T he molecular cloning of IgE-receptors has helped to classify these receptors into two very different families of proteins. The high affinity IgE receptor (FceRI)* is a noncovalent tetrameric complex of an ~x chain, a 13 chain, and two disulfide-linked 3' chains (1, 2) . The high affinity binding site of FceRI is on the oz chain, a structure homologous to other Fc receptors and a member of the Ig superfamily. By contrast, low af~nity IgE-binding structures are part of the lectinlike receptor family. One of these, FceRII or CD23, belongs to the calcium-dependent class of animal lectins (3, 4) and the other, Mac-2, also called CBP35 and eBP (5, 6) , is of the thiol-dependent class of animal lectins.
The tissue distribution and function of these receptors are also very different. The high affinity IgE receptor is found on the surface of mast cells, basophils (1) , and Langerhans cells (7) . Crosslinking of this receptor via IgE and antigen results in release of the mediators that cause the symptoms 1 Abbreviations used in this paper: F(ab')z, antigen binding fragment of immunoglobulin molecule obtained by pepsin digestion; Fc, constant fragment of immunoglobulin molecule; FcylLII, low affinity receptor for IgG; Fc'yRlI1, low affinity receptor for IgG; FceRI, high affinity receptor for IgE; and FceRII, low affinity receptor for IgE. of allergic diseases. CD23 in humans is expressed on a wide variety of hemopoietic cells, among them B and T cells, but in mice, the expression of CD23 appears to be restricted to B cells (3) . The role of CD23 is not yet completely understood, but it has been proposed to regulate IgE synthesis, to endocytose IgE-immune complexes in B cells, and to serve as an adhesion molecule. Mac-2 was originally described as a macrophage cell surface marker (8) , but it is also expressed in mast cells and fibroblasts (5, 6) . In spite of the lack of a typical transmembrane domain, a proportion of Mac-2 molecules in these cells are attached to the cell surface. The mechanism of membrane anchoring may involve binding to cell surface glycoconjugates, because incubation of cells with lactose disrupts the attachment (9) . In solution, Mac-2 binds IgE, but this binding is carbohydrate dependent and has not been demonstrated for surface-expressed molecules, so its physiological relevance is at best speculative.
More than a decade ago, two molecules with different molecular weight were isolated by affinity chromatography on IgE-Sepharose from extracts of rat basophilic leukemia cells and rat mast cells (10, 11) . Then rat basophilic leukemia cells were shown to express IgG receptors also capable of binding IgE (12) . In fact, these receptors seemed to have a greater a~nity for rat IgE than for rat IgG (12, 13) . Other reports indicated that rat IgE could inhibit the binding of IgG to rat lymphocytes (14) or to rat macrophages (15) . However, this inhibition was characterized as unidirectional and was thought to be unique for rat cells (16) .
Our original goal was to characterize the putative low affinity IgE/IgG receptor on rodent mast cells by molecular methods. Despite the restriction of earlier studies to the rat system, we decided to use mouse mast cells because antibodies are available against the various structures known to bind IgE or IgG. We found that the two low affinity receptors for IgG (Fc3'RII/III) known to be expressed on the surface of mouse mast cells (17, 18) and macrophages (19) , are also low affinity receptors for IgE.
Materials and Methods
Iraraunoglobulins. Igs (21) was purified from ascites as previously described (22) or it was purified by ion exchange chromatography on DEAE-Trisacryl (IBF Biotechnics, Columbia, MD) from culture supernatant of the hybridoma grown in Protein-Free Hybridoma Medium (Gibeo BRL, Grand Island, NY) in a Mini Flo-Path bioreactor (Amicon, Beverly, MA). Mouse anti-DNP IgE was labded with FITC by standard procedures (23) . Rabbit antimouse IgE (22) and mouse anti-DNP IgG (24) were prepared as described. The rat mAb 2.4G2 (anti-mouse Fc3`RII and -Ill) (25) was purified from tissue culture supernatant by Protein-G affinity chromatography (Pharmacia LKB Biotechnology, Piscataway, NJ). To make oligomers, 100 mg/ml rabbit IgG or mouse monoclonal IgE were chemically crosslinked using dimethyl suberimidate (Pierce Chemical Co., Rockford, IL) (12) at a crosslinker/protein molar ratio of 10:1 at 30~ for 3 h. Rabbit IgG dimers were obtained from this preparation by size separation on Sephacryl S-300 HR (Pharmacia LKB Biotechnology). They were radioiodinated using chloramine T as described (23) . To prepare immune complexes, 1 mg/ml anti-DNP IgG or anti-DNP IgE were incubated with DNPalbumin (Calbiochem Corp., LaJolh, CA) at molar ratios of 1:1-20:1 at 4~ for 1 h and used without further washing. Monomeric IgG and IgE were separated from aggregates by centrifuging at 130,000 g for 45 min in an Airfuge (Beckman Instruments, Inc., Fullerton, CA). Only the upper 3/4 of the samples were used.
Cells. COS-7, J774A.1, P388D1, and P815 (American Type Culture Collection, Rockville, MD) were grown in DMEM with 2 mM glutamine, 10% FCS, 100 U/ml penicillin, and 100/zg/ml streptomycin (Biofluids Inc., Rockville, MD) at 37~ in a humidified atmosphere containing 5% CO2. The mouse mast call line C1.MC/C57.1 (C57.1) (26), a gift of S. J. Galli (Beth Israel Hospital, Boston, MA), was maintained in DMEM as were the other cell lines, except for the further addition of 5 #M 13-ME.
Expression Vectors. cDNAs encoding mouse Fc3`RII and the c~ chain of Fc3`RIII (19) were gifts ofJ. V. Ravetch (Memorial SloanKettering Cancer Center, New York). The cDNA for the 3, subunit common to mouse FceRI and F~RIII was previously described (27) . The expression vector pCDbSRot296 (28) For binding of monomeric IgE or IgE-immune complexes, 10 s cells were incubated with 10/~g/ml of monomeric IgE-FITC or immune complexes oflgE-FITC and DNP-albumin at 4~ for 2 h and then washed twice with PBS containing 0.1% BSA and 0.1% NAN3. For removal of cell surface Mac-2, the same buffer was used with the further addition of 25 mM lactose (8) . For binding of oligomeric IgG, the cells were incubated with 10/~g/ml of rabbit IgG oligomer at 4~ for 2 h and washed. Goat anti-rabbit IgG F(ab')2-FITC was used as the second antibody to detect IgG binding to the cells. Unstained cells or the cells stained with the second antibody alone were used as negative controls. For competitive inhibition, cells were preincubated with 50/~g/ml 2.4(32 and/or 50 #g/ml unlabeled IgE at 4~ for 2 h before addition of oligomeric IgG or labeled IgE.
Competition Binding Experiments. Competitive binding of t2sI-
labeled rabbit IgG dimers and unlabeled monomeric Igs to transfected cells was studied as previously described (12) . Briefly, cells transfected with either Fc3`RII or -III or the 3` subunit alone were incubated with 10/~g/ml radiolabeled rabbit IgG dimer (corresponding to 6.7 x 10 -s M IgG molecules) and varying concentrations of unlabeled monomeric mouse monoclonal IgG2b, rabbit IgG, or mouse monoclonal anti-DNP IgE (molar ratios of monomer/dimer 0.6:1-150:1, based on IgG molecules). The cell density was 2 x 107/ml, the buffer was PBS containing 0.2% BSA, and the incubation was at 4~ for 2 h. Cells were centrifuged through phthalate oil (6 volume parts dibutyl phthalate, 4 volume parts bis(ethylhexyl)phthalate) to separate bound from unbound ligand. Percent cell-bound radioactivity was calculated by dividing cpm in the cell pellet by total cpm. Nonspedfic binding was determined with transfectants expressing 3` alone and subtracted from the percent binding value to give percent specific binding. The degree of inhibition by various monomeric Igs was calculated by setting the specific binding in the absence of inhibitors equal to 0% inhibition. 100% inhibition was defined as absence of specific binding as a consequence of inhibition. Saturation binding assays with increasing amounts of radiolabeled IgG dimers were performed before the competition binding experiments to verify expression of the receptors and to determine optimal conditions. Serotonin Release. C57.1 cells were cultured with 1/~Ci/ml of 5-[1,2-3H(N)]-hydroxytryptamine binoxalate ([~H]-serotonin) (DuPont Co., Wilmington, DE) for 16 h. All procedures after labeling were performed in buffer containing 25 mM Na2Pipes (pH 7.1), 100 mM NaCI, 5 mM KC1, 0.4 mM MgC12, 1 mM CaC12, 5.6 mM D-glucose, and 0.1% BSA (30) . Cells were saturated with monomeric IgE, 2.4G2, or both at 37~ for 1 h and washed. The cells were challenged by rabbit anti-mouse IgE or multivalent antigen (DNP-albumin) for triggering through FceRI.
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IgE Binding to Fc3,1LII and Fc3,RIII For triggering through FC3'Ks, receptor-bound 2.4G2 was crosslinked with anti-rat IgG (Fc-specific). When IgE and/or 2.4G2 were used as inhibitors, these inhibitors were resupplemented after saturation and washing, and the cells were challenged by IgG-or IgE-immune complexes. The reaction was stopped after 30 min by placing the tubes on ice and sedimenting the cells for 3 min at 4,000 rpm in a microfuge. Radioactivity was determined separately in the pellet and the supernatant. Percent release was calculated by dividing counts per minute in the supematant by total counts/min.
Results and Discussion
Cell Surface Receptors on C57.1. Our first goal was to establish unequivocally whether IgE binds to a second site on mast cells other than FceKI. This, and the identification of the binding site, requires antibodies against cell surface proreins known to bind IgG or IgE. For murine ceils, several useful antibodies are available, such as 2.4G2, which binds to the extraceilular domains of the highly homologous Fc'/KII and -III receptors and blocks the binding of IgG (25), or B3B4, which recognizes mouse FceRII (20) . Comparable anti-rat reagents are not known. Therefore, we analyzed the mouse mast call line C57.1 rather than the rat cell line RBL, which had been studied previously. We first characterized relevant ceil surface proteins on this cell line (Table 1) . C57.1 is FceKI + , FceKII-, F~KII/III + , and Mac-2 + . Mac-2 can be removed from the cell surface by lactose, as has been described for RBL (9) . The cell line responds to engagement of FceKI in the same way as R.BL (30a).
2.4G2-inhibitable Binding of lgE-immune Complexes to Mast Cells.
To investigate binding of Igs to their surface, C57.1 ceils were incubated with monomeric antibody or with immune complexes and analyzed by flow cytometry. Monomeric IgE strongly binds to C57.1 (Fig. 1 A) . This binding is completely inhibited by excess unlabeled monomeric IgE (50 #g/ml) (Fig. 1 B) . There is no further inhibition when both excess IgE and 2.4G2 are employed (Fig. 1 C) . This is consistent with the presence of a single dass of high affinity binding sites for IgE on these ceils, i.e., FceKI receptors. IgE-immune complexes also strongly bind to C57.1 (Fig. 1 D) . In contrast to the binding of monomeric IgE, the binding of im- mune complexes is not completely inhibited by excess monomeric IgE (Fig. 1 E) , indicating that IgE-immune complexes do indeed bind to a second site in addition to FceKI. However, the binding of immune complexes is completely blocked by the combination of excess monomeric IgE and FcyKII/IIIspecific 2.4G2 (Fig. 1 F) . This demonstrates that the staining not inhibited by monomeric IgE is due to a cell surface structure recognized by 2.4G2. Further binding, which could be attributed to other structures such as Mac-2, is not detected. These experiments were performed with monodonal anti-DNP IgE purified from serum-flee bioreactor supernatant to ensure there is no contamination with other Ig dasses and repeated with a preparation of the same antibody from ascites. No difference between the two preparations was detected. Oligomerized IgG binds to C57.1 (Fig. 1 G) . It is not surprising that its binding is inhibited by 2.4G2 ( Fig.  1 H) , and also by IgE-immune complexes (Fig. 1/) 
Binding of lgE-immune Complexes to Macrophage Cell Lines and to a Fc6RI-deficient Mast Cell Line. We investigated
whether this low affinity, 2.4G2-reactive binding site was also present on ceil types that express Fc'yKII/III receptors but not FceRI. J774, a mouse monocyte-macrophage cell line (31), does not bind monomeric IgE (Fig. 2 A) , but does bind IgE-immune complexes to a site that is blocked by 2.4G2 (Fig. 2 B) . In the same way, 2.4G2 blocks binding of oligomeric IgG (Fig. 2 C) . J774 stains with an anti-rat Mac-2 antiserum, which crossreacts with the mouse protein. The staining is abolished by prior incubation of the cells with 25 mM lactose, indicating that Mac-2 binds to cell surface conjugates on J774. However, the binding of IgE-immune complexes to J774 is not affected by this treatment (data not shown). Together with the lack of a third binding site for IgE on C57.1, this observation excludes Mac-2 from the ranks of functional cell surface IgE receptors. The ability of cell surface Mac-2 to bind IgE has also been questioned on theoretical grounds (9), because the protein, which does not have a transmembrane region, apparently attaches to the cell surface by binding a membrane glycoconjugate and cannot bind IgE simultaneously. Essentially the same results were obtained with P388D1 (macrophage-like) (32) , and the mastocytomalike P815 (33) (data not shown), which express Fc3,KII and -III but not FcdLI (18, 34) . This is further evidence that the low affinity binding site for IgE on mast cells and macrophages is an Fc'yKII/III receptor. Fig. 3 E and F) . Cells which transiently expressed Fc'yRII bound IgE-immune complexes (Fig.  3 B) , as well as oligomeric IgG (Fig. 3 A) . In both cases the binding was completely inhibited by 2.4G2. A similar staining was observed with cells expressing Fcq~RIII (Fig. 3,  C and D) . This result shows that the so-called IgG receptors FcyRII and -III are not isotype specific; they bind IgE and are thus functional Fce receptors. IgE. The molar ratio of monomers/dimers (based on IgG molecules) varied between 0.6 and 150. IgE was less efficient than either rabbit IgG or mouse IgG2b at competing with dimers for binding to Fc'yKII (Fig. 4, left) , and as efficient as rabbit IgG, but less so than mouse IgG2b, at competing for FcyKIII (Fig. 4, right) . The approximate association con- 
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x 10 sM -1,9.1 x 10 sM -rand3. (Table 2; 25.2% release, inhibited to 1.3 % by prior blocking with 2.4G2) or by crosslinking receptor-bound 2.4G2 with a secondary anti-rat antibody (33.2% release). There is no response to 2.4G2 alone (1.0% release), presumably because it is an insufficient stimulus to crosslink Fc3~RII/III to mere dimers. Even with optimized crosslinking, the response to Fc'yR stimulation is much weaker than that to FceRI stimulation (62.6% release after crosslinking of FceRI-bound IgE). We do not know whether this reflects merely a difference in receptor number or a difference in the signaling mechanism.
We then investigated whether stimulation through F~ILII/ III contributes to activation when C57.1 cells are triggered by immune complexes of monodonal anti-DNP IgE and DNPalbumin (Fig. 5, left) or by chemically crosslinked IgE (Fig.   5, right) . With both of these triggering agents a comparable plateau of serotonin release ('~70%) is reached. 2.4G2 alone does not inhibit release. However, if binding of the IgEimmune complexes to FceRI is selectively inhibited with monomeric IgE, serotonin release is reduced to about one half of the release observed without inhibition. There is an even greater inhibition when both FceRI and Fc3,RII/III are blocked. The magnitude of this further inhibition corresponds well with that of IgG-mediated release through Fc'yRII/III. IgE can thus trigger mast cells through both FceRI and FcyRII/III.
To summarize, we have unequivocally shown that: mouse IgE binds with low affinity to a site on mast cells other than FcetLI; that this site corresponds to the mouse IgG receptor Fc3~RII/III also found on cell types such as macrophages; that the affinity of IgE for the receptors is comparable with that of IgG; and that the binding is functional, because it contributes to mast cell activation. Our goal is now to investigate whether these findings are also relevant to the human system. In that case, our findings would have dramatic implications for explaining the role of IgE in parasitic diseases (39) . It might be argued that in view of the serum levels of IgE, binding of IgE to Fc3,RII or Fc~/RIII will not occur under physiological conditions, and in any case will be competed by much higher levels of IgG. However, the affinity of these receptors is comparably low for IgG. In fact, normal macrophages are capable of binding IgG-immune complexes because most of the receptors are empty in physiological conditions. It is therefore probable that IgE-as well as IgGimmune complexes will bind to these receptors and activate relevant defence systems, particularly in situ, where the concentration of immune complexes relative to monomeric ligand might be much higher than in the serum.
